Equity markets in India and the US: Sensex, Nifty, Wall Street indices, IPOs and the corporate news that moves stocks.

Decidr AI Industries Ltd (ASX:DAI) is in focus today as enterprise artificial intelligence strategy and commercial positioning shapes the latest discussion across ASX Growth Stocks and the broader Australian market.

Asia chip, tech stocks track Wall St gains as yields fall

Stocks rise as oil dips, yen wobbles ahead of BOJ

Direxion Daily PANW Bull 2X ETF (NASDAQ:PALU – Get Free Report) saw a significant growth in short interest in August. As of August 31st, there was short interest totaling 30,366 shares, a growth of 72.4% from the August 15th total of 17,614 shares. Currently, 5.3% of the company’s stock are sold short. Based on an [...]

Constellation Software (OTCMKTS:CNSWF – Get Free Report) and Karooooo (NASDAQ:KARO – Get Free Report) are both technology companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings. Analyst Recommendations This is a breakdown of current ratings [...]

Orion180 Insurance prices US IPO below range, raises $240 million
Investors sold $31-billion in U.S. stocks and equity funds in July, according to Statscan, the largest monthly net exodus from American markets ever

Stocks to watch, 18 Sept: Stocks like Skyways Air Services, Bharat Forge, InterGlobe Aviation, Petronet LNG, Bharat Electronics, GPT Infraprojects, PTC India, NLC India, and Wipro will be in focus on Setpember 18.

Wall Street bounced back on Thursday as easing oil prices, dropping US Treasury yields and solid labor data helped markets move beyond the Federal Reserve's first interest rate hike in more than three years.

The Nifty 50 may face immediate resistance in the 23,300-23,400 zone, and a decisive move above this range could drive the index towards 23,500-23,600. On the downside, the major support is placed in the 23,100-23,000 zone.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that the U.S. Food and Drug Administration’s (FDA) Cosmetics Regulatory Science Branch has licensed ADMET Predictor® to support its computational research for modern cosmetic safety assessment. The contract expands the use of Simulations Plus technology
Each story below is a short excerpt from reporting by an established publisher, shown in the publisher's own words. We credit the publisher and link to the original article. Stories are matched to this topic by keyword and shown newest first.